Riken Genesis and Burning Rock Biotech (BNR) announced that the OncoGuide OncoScreen Plus CDx System based on OncoScreen Plus to be used as a companion diagnostic for AstraZeneca’s (AZN) capivasertib has received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNR: